The highly significant overexpression of both genes (p < 0.001) combined with substantial fold-changes (SNAIL: 2.55, FOXC2: 2.70) establishes these molecules as reliable indicators of metastatic disease progression and represents a major advancement in understanding breast cancer stem cell biology. This evidence concerns the gene FOXC2 and breast carcinoma.